140 related articles for article (PubMed ID: 19583677)
21. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Rost KL; Brockmöller J; Esdorn F; Roots I
J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
[TBL] [Abstract][Full Text] [Related]
22. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
[TBL] [Abstract][Full Text] [Related]
23. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
24. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
[TBL] [Abstract][Full Text] [Related]
25. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
[TBL] [Abstract][Full Text] [Related]
26. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.
Payan M; Rouini MR; Tajik N; Ghahremani MH; Tahvilian R
Daru; 2014 Dec; 22(1):81. PubMed ID: 25498969
[TBL] [Abstract][Full Text] [Related]
27. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
[TBL] [Abstract][Full Text] [Related]
29. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Rost KL; Roots I
Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
Hu YR; Qiao HL; Kan QC
Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
[TBL] [Abstract][Full Text] [Related]
32. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
[TBL] [Abstract][Full Text] [Related]
33. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
[TBL] [Abstract][Full Text] [Related]
34. Artemisinin induces omeprazole metabolism in human beings.
Svensson US; Ashton M; Trinh NH; Bertilsson L; Dinh XH; Nguyen VH; Nguyen TN; Nguyen DS; Lykkesfeldt J; Le DC
Clin Pharmacol Ther; 1998 Aug; 64(2):160-7. PubMed ID: 9728896
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.
Yin OQ; Tomlinson B; Waye MM; Chow AH; Chow MS
Pharmacogenetics; 2004 Dec; 14(12):841-50. PubMed ID: 15608563
[TBL] [Abstract][Full Text] [Related]
36. Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.
Niioka T; Uno T; Sugimoto K; Sugawara K; Hayakari M; Tateishi T
Eur J Clin Pharmacol; 2007 Nov; 63(11):1031-8. PubMed ID: 17701405
[TBL] [Abstract][Full Text] [Related]
37. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.
Park S; Hyun YJ; Kim YR; Lee JH; Ryu S; Kim JM; Oh WY; Na HS; Lee JG; Seo DW; Hwang IY; Park Z; Jang IJ; Oh J; Choi SE
J Korean Med Sci; 2017 May; 32(5):729-736. PubMed ID: 28378544
[TBL] [Abstract][Full Text] [Related]
38. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
39. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
40. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
